NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) resulting from allegations that Intercept may have issued materially misleading business information to the investing public.
On October 8, 2020, news outlets reported that Intercept was “facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”
On this news, Intercept’s stock price fell $3.30 per share, or 8%, to close at $37.69 per share on October 8, 2020, damaging investors.
Rosen Law Firm is preparing a securities lawsuit on behalf of Intercept shareholders. If you purchased securities of Intercept please visit the firm’s website at http://www.rosenlegal.com/cases-register-1973.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at mailto:firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Attorney Advertising. Prior results do not guarantee a similar outcome.